Annexon Inc

NASDAQ:ANNXUnited States

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.

Contact Information

Headquarters

1400 SIERRA POINT PARKWAY BLDG C SUITE 200BRISBANE, CA, United States 94005

Phone

650-822-5500

Fax

650-636-9773

Executives

Independent Chairman of the Board

Thomas Wiggans

President, Chief Executive Officer, Director

Douglas Love

Chief Financial Officer, Executive Vice President

Jennifer Lew

Executive Vice President, Chief Scientific Officer

Dean Artis

Executive Vice President, Chief Medical Officer

Jamie Dananberg